AI in Life Sciences is a podcast that keeps a finger on the pulse of technological advancement within the healthcare and pharmaceutical fields. In this episode, we'll take a deep dive into Novartis AG's recent nomination of former Bristol Myers CEO Giovanni Caforio as incoming chair, examining what this could mean for the company's future amidst the global competition. We'll then switch gears to discuss the ongoing reorganization of AI-driven drug developer, BenevolentAI, and how shifting priorities are impacting its workforce. The episode will also cover Ultrahuman's anticipated expansion into the US market through the establishment of a manufacturing center in Indiana, a move benefiting domestic production and job creation. Finally, we'll review Basware's new AP Protect tool, designed to detect errors and fraudulent activities in finance teams using advanced AI algorithms. Join us for thought-provoking insights into how AI continues to revolutionize the life sciences sector.